최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Cancer research and treatment : official journal of Korean Cancer Association, v.49 no.2, 2017년, pp.454 - 463
Beom, Seung Hoon (Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea) , Oh, Jisu (Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea) , Kim, Tae-Yong (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Lee, Kyung-Hun (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Yang, Yaewon (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Suh, Koung Jin (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Moon, Hyeong-Gon (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Han, Sae-Won (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Oh, Do-Youn (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea Korea<) , Han, Wonshik , Kim, Tae-You , Noh, Dong-Young , Im, Seock-Ah
PurposeLetrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)–positive metastatic breast cancer (MBC). To the best of our knowledge, there have been no reports of the clinical outcom...
1 Ferlay J Soerjomataram I Dikshit R Eser S Mathers C Rebelo M Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 2015 136 E359 86 25220842
2 Jung KW Won YJ Kong HJ Oh CM Seo HG Lee JS Prediction of cancer incidence and mortality in Korea, 2013 Cancer Res Treat 2013 45 15 21 23613666
3 Wilcken N Hornbuckle J Ghersi D Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer Cochrane Database Syst Rev 2003 2 CD002747 12804433
4 Paridaens RJ Dirix LY Beex LV Nooij M Cameron DA Cufer T Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group J Clin Oncol 2008 26 4883 90 18794551
5 Bonneterre J Thurlimann B Robertson JF Krzakowski M Mauriac L Koralewski P Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study J Clin Oncol 2000 18 3748 57 11078487
6 Mouridsen H Gershanovich M Sun Y Perez-Carrion R Boni C Monnier A Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 2003 21 2101 9 12775735
7 Carlson RW Allred DC Anderson BO Burstein HJ Carter WB Edge SB Breast cancer: clinical practice guidelines in oncology J Natl Compr Canc Netw 2009 7 122 92 19200416
8 Cheang MC Chia SK Voduc D Gao D Leung S Snider J Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 2009 101 736 50 19436038
9 Nabholtz JM Buzdar A Pollak M Harwin W Burton G Mangalik A Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol 2000 18 3758 67 11078488
10 Kim Z Min SY Yoon CS Jung KW Ko BS Kang E The basic facts of Korean breast cancer in 2012: results from a nationwide survey and breast cancer registry database J Breast Cancer 2015 18 103 11 26155285
11 Mouridsen H Gershanovich M Sun Y Perez-Carrion R Boni C Monnier A Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 2001 19 2596 606 11352951
12 Gibson L Lawrence D Dawson C Bliss J Aromatase inhibitors fortreatment of advanced breast cancerin postmenopausal women Cochrane Database Syst Rev 2009 4 CD003370 19821307
13 Kataja V Castiglione M ESMO Guidelines Working Group Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 2008 19 Suppl 2 ii11 3 18456744
14 Masri S Phung S Wang X Wu X Yuan YC Wagman L Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor Cancer Res 2008 68 4910 8 18559539
15 Murphy CG Dickler MN Endocrine resistance in hormoneresponsive breast cancer: mechanisms and therapeutic strategies Endocr Relat Cancer 2016 23 R337 52 27406875
16 Finn RS Crown JP Lang I Boer K Bondarenko IM Kulyk SO The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 2015 16 25 35 25524798
17 Turner NC Ro J Andre F Loi S Verma S Iwata H Palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 2015 373 209 19 26030518
18 Mouridsen HT Letrozole in advanced breast cancer: the PO25 trial Breast Cancer Res Treat 2007 105 Suppl 1 19 29 17333340
※ AI-Helper는 부적절한 답변을 할 수 있습니다.